Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

Novo Nordisk launched its latest campaign – My Ozempic ... said the team was initially inspired to create the campaign when the FDA expanded Ozempic’s indication to treat chronic kidney disease for ...

Singer Michael Trotter Jr of The War and Treaty, chef Franklin Becker of “Top Chef Masters,” and a beauty salon owner ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Novo Nordisk ... CV disease, and to reduce the sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and CV death in adults with T2D and chronic kidney disease.

In recent news, FDA has approved Ozempic to reduce risk of kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Novo Nordisk also has introduced ...

PLAINSBORO, N.J., March 3, 2025 /PRNewswire/ -- Novo Nordisk launched "My Ozempic ® Era" today, a national campaign which spotlights the longstanding Ozempic ® patient community by sharing ...

Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the science behind weight management, and the role of medications like Ozempic in ...

Those who live with type 2 diabetes have an increased risk of developing chronic kidney disease and are more ... of U.S. Diabetes Therapeutic Area at Novo Nordisk. "By spotlighting the real ...

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.